Home | Publications | Diseases | AIDS & HIV place holder
place holder place holder

AIDS & HIV

Stakeholder Insight: HIV

A way of life

Publication Date   October 2005
Publisher   Datamonitor
Product Type   Report
Pages   284
ISBN Number   not applicable
Product Code   DAT380
Ask a question about this product?

Price £8,695.00

approximately: $12,913 | €10,232

Summary


HIV is now considered a chronic, manageable disease. However the lifelong therapy required to control HIV means considerations such as patient quality of life and cost of therapy are becoming increasingly influential in product choice. Consequently the development of new products which offer limited improvements in efficacy but better convenience and tolerability has changed prescription practices

Highlights

Increasing transmission by heterosexual contact suggests both an absence and/or ineffectiveness of HIV awareness and education programs. It also exposes more females to the HIV virus, leading to unique disease management issues.The success of HAART in prolonging survival within the HIV population introduces new psychosocial challenges beyond pharmaceutical management. Age-related conditions, comorbidities and the desire to conceive call for a new multi-faceted pattern of patient careDatamonitor physician research indicates that of 273,000 first-line treated individuals, globally 79% are now receiving fixed dosed combinations (FDCs). While guidelines and HIV specialists have embraced their convenience and simplicity, the unstructured nature of later lines of therapy requires increasing individualization

Scope

  • Analysis of current treatment regimens and unmet needs, based on a survey of 180 physicians in the seven major pharma markets around the world
  • Current epidemiology of HIV in the seven major markets, including prevalence, age and gender splits, with analysis of diagnosis and chain of care
  • A detailed examination of the numbers of patients on each line of therapy, which drugs they are taking and for what reasons is provided
  • An assessment of key unmet needs within HIV and the changes in mortality since the introduction of HAART is included

Reasons to Purchase

  • Understand the unique disease management issues raised by increasing heterosexual transmission of HIV to females
  • Identify opportunities for new patterns of patient care following the success of HAART in prolonging survival
  • Explore unmet needs in HIV therapy, as identified by treating physicians, and including increased individualization in later-line therapy

Content


  • Chapter 1 Executive Summary
    • Scope of the analysis
    • Datamonitor insight into the HIV market
  • Chapter 2 Introduction And Scope
    • Coverage of the Stakeholder Insight Survey
    • Epidemiology
    • Diagnosis and treatment rates
    • Antiretroviral prescriptions
    • Prescription choice
    • Country level treatment trees
  • Chapter 3 Country Treatment Trees
    • US
    • Japan
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Seven major markets
  • Chapter 4 Epidemiology And Patient Segmentation
    • Disease definition and classification
    • The HIV lifecycle - numerous steps has created several therapeutic targets
    • HIV subtypes - diversity throughout the world
    • HIV epidemiology - changing demographics creating new unmet needs
    • A growing proportion of women are affected by HIV/AIDS
    • The aging of the HIV population has created new therapeutic issues
    • Key patient segmentations
    • Newly diagnosed versus follow-up patients
    • Multi-drug resistant patients
    • Hepatitis co-infection
    • Pregnancy
    • Routes of transmission
  • Chapter 5 Diagnosis And Treatment Options
    • Presentation and diagnosis
    • Perception of risk drives HIV testing
    • HIV diagnostics are effective and easy to use
    • ELISA
    • PCR
    • Others
    • Advances in diagnostics has led to quicker and easier HIV tests
    • Treatment guidelines
    • Treatment rates
    • Treatment options
    • Class overviews
  • Chapter 6 Prescribing Trends And Influencing Factors
    • First-line therapy
    • Prescription choice
    • FDC backbones dominate first-line therapy
    • Switching from first- to second-line therapy
    • Factors affecting patient quality of life are key drivers of regime changes
    • The M184V mutation is the most common in first-line patients, but NNRTI resistance is also a frequent driver of switching
    • Second-line therapy
    • Prescription choice
    • PI usage is more predominant in second-line therapy
    • Switching from second- to third-line therapy
    • Tenofovir- and PI-associated mutations are more common in second-line patients
    • Third- and later-line therapy
    • Prescription choice
    • Fuzeon is increasingly being used in third- and later-lines of therapy
    • Factors influencing prescription choice
    • Patient quality of life issues are playing an increasingly important role
    • Although a growing concern, cost rarely plays a part in the physician decision
    • The increasing importance of cost in prescription decisions
    • How cost-effective is HAART?
    • Cost of first-line therapy in the US and the UK - a comparison
  • Chapter 7 Improving Treatment Outcomes
    • Treatment outcomes
    • Advances in therapy mean fewer patients progress to AIDS
    • Morbidity and mortality have declined significantly over the last decade
    • HIV accounts for a small proportion of total deaths in the developed world
    • Antiretroviral therapy has led to significant gains in terms of survival years and a reduced incidence of opportunistic infections
    • Unmet needs
    • Resistance to currently available therapy is a major unmet need for certain classes
    • Although there have been considerable improvements in therapy, important unmet needs remain
  • Chapter 8 Opinion Leader And Stakeholder Transcripts
  • Appendix A - Additional Data
    • Pacific Rim definition
  • Appendix B - Bibliography
    • Journal articles
    • Conference abstracts
    • Press Releases
    • Websites
    • Guidelines
    • Epidemiological data
  • Appendix C
    • Physician research methodology
    • Physician sample breakdown
    • US
    • Japan
    • France
    • Germany
    • Italy
    • Spain
    • UK
  • Appendix D
    • The survey questionnaire
    • Section 1: Epidemiology
    • Section 2: Diagnosis and treatment rates
    • Section 3: Antiretroviral prescriptions
    • Section 4: Prescription choice
    • The opinion leader discussion guide
    • Section 1 - Epidemiology
    • Section 2 - Presentation and diagnosis
    • Section 3 - Treatment practices
    • Section 4 - Prescription choice
    • Section 5 - Resistance issues
    • Section 6 - Unmet needs
    • Section 7 - Pipeline products
    • Disclaimer